- Conditions
- Body Weight
- Interventions
- Weight Management Formulation, Placebo, Handout with Suggestions for Healthy Eating and Overall Health
- Dietary Supplement · Other
- Lead sponsor
- Supplement Formulators, Inc.
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Fort Lauderdale, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2185–2208
of 18,305
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rotator Cuff Tendinopathy
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- La Mesa, California • Van Nuys, California • Winter Park, Florida + 1 more
- Conditions
- Osteoarthritis Post-meniscectomy
- Interventions
- Bone Marrow Aspirate Concentrate, Standard Meniscectomy
- Biological · Procedure
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia
- Interventions
- Ibuprofen and acetaminophen, Ibuprofen and placebo
- Drug
- Lead sponsor
- University of South Alabama
- Other
- Eligibility
- 5 Days to 21 Days
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Mobile, Alabama
- Conditions
- Schizophrenia
- Interventions
- Drug: EVP-6308, Placebo
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 48
- States / cities
- Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more
- Conditions
- Healthy
- Interventions
- SAR231893 (REGN668) DP1, SAR231893 (REGN668) DP2
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Alzheimer's Disease
- Interventions
- MK-1167, Donepezil, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Hallandale, Florida • Decatur, Georgia • Savannah, Georgia
- Conditions
- Peripheral Neuropathy
- Interventions
- MIRE, Sham Device
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Non-segmental Vitiligo
- Interventions
- AS012, Placebo
- Drug
- Lead sponsor
- Ache Laboratorios Farmaceuticos S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Bryant, Arkansas • Fremont, California + 16 more
- Conditions
- Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
- Interventions
- Afimetoran, Placebo
- Drug
- Lead sponsor
- Beeline Medicines Corporation
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- San Diego, California • DeBary, Florida • Missoula, Montana
- Conditions
- HIV Infections
- Interventions
- Racivir, a non-nucleoside reverse transcriptase inhibitor
- Drug
- Lead sponsor
- Pharmasset
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • The Bronx, New York • Columbia, South Carolina
- Conditions
- Asthma
- Interventions
- albuterol sulfate inhalation aerosol
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- Up to 23 Months
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 27
- States / cities
- Hoover, Alabama • Fort Mohave, Arizona • Jonesboro, Arkansas + 24 more
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- CRD-4730, Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Pasadena, California • Bloomfield Hills, Michigan
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Nasal Cavity and Paranasal Sinus Carcinoma, Oral Cavity Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Hypopharyngeal Carcinoma, Recurrent Laryngeal Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Carcinoma, Recurrent Oral Cavity Carcinoma, Recurrent Oropharyngeal Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Celecoxib, Placebo, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
- Interventions
- AAV1/SERCA2a (MYDICAR), Placebo
- Genetic
- Lead sponsor
- Celladon Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Non-small Cell Lung Cancer, Vomiting, Nausea, Emesis
- Interventions
- FOSAPREPITANT (Emend), Placebo
- Drug
- Lead sponsor
- Ajeet Gajra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Breast Neoplasms
- Interventions
- Xentuzumab, Placebo, Everolimus, Exemestane
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 16
- States / cities
- Chandler, Arizona • Goodyear, Arizona • Beverly Hills, California + 13 more
- Conditions
- Tinnitus, Subjective, Hyperacusis, Hearing Disorders
- Interventions
- Transcranial Direct Current Stimulation (tDCS), Sham TDCS
- Device
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Vortioxetine, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 33
- States / cities
- Anaheim, California • Arcadia, California • Irvine, California + 30 more
- Conditions
- Irritability Associated With Autism Spectrum Disorder
- Interventions
- Lumateperone high dose, Lumateperone low dose, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 35
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 28 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- EVO756, Placebo control
- Drug
- Lead sponsor
- Evommune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fremont, California + 38 more
- Conditions
- Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
- Interventions
- Glycerinated peanut allergenic extract, Placebo for peanut extract (glycerin)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- empasiprubart, IVIg, empasiprubart-placebo, IVIg-placebo
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Rancho Mirage, California + 15 more